Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial.

Background: Trafermin (basic fibroblast growth factor) has been shown to reduce infarct volume in acute ischemic stroke models, and to promote functional recovery and new synapse formation when given to animals with completed cerebral infarction. A previous study in acute stroke patients suggested that trafermin was safe and well tolerated when given over a 3-hour period over a wide dose range.

Methods And Results: Double-blind, parallel group, placebo-controlled trial of a single 24-hour intravenous infusion of trafermin.